Receipt of Hon''ble NCLT Order approving acquisition of Genrx Pharmaceuticals Private Limited on a going concern basis

Ref: BHL/ STEX 43/ 2026-27 Date: October 14, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex Bandra (East) Mumbai – 400 001 Mumbai-400051 Scrip Code: 539872 Symbol: BAJAJHCARE Subject: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Receipt of Hon’ble NCLT Order approving Acquisition of Genrx Pharmaceuticals Private Limited on a Going Concern Basis Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), and in continuation of our earlier disclosures dated April 5, 2025 and April 7, 2025, regarding the acquisition of Genrx Pharmaceuticals Private Limited (in Liquidation), we wish to inform you that the Hon’ble National Company Law Tribunal (“NCLT”), Mumbai Bench, vide its order dated October 13, 2026, has approved the acquisition of Genrx Pharmaceuticals Private Limited on a going concern basis. The Company downloaded the aforesaid order from the official website of the Hon’ble National Company Law Tribunal on October 13, 2026. The brief details of the aforesaid order, as required under Regulation 30(13) of the SEBI Listing Regulations read with the Industry Standards Note on Regulation 30, are enclosed herewith as “Annexure I” Further, pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended & as per the Company’s code of Internal Procedures and Conduct for Regulating, Monitoring & Reporting of trading in securities, the Trading window for dealing in securities of the Bajaj Healthcare Limited shall continue to remain closed for all Designated Persons including their immediate relatives in terms of our earlier disclosure dated September 23, 2026. You are requested to take the same on record. Thanking You, For and on behalf of Bajaj Healthcare Limited Monica Tanwar Company Secretary & Compliance Officer Annexure I Date: October 14, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex Bandra (East) Mumbai – 400 001 Mumbai-400051 Scrip Code: 539872 Symbol: BAJAJHCARE Dear Sir/Madam, Re: Receipt of Hon’ble NCLT Order approving Acquisition of Genrx Pharmaceuticals Private Limited on a Going Concern Basis In respect of the captioned matter, We, the undersigned, state and declare that the information and details provided in Form A, in compliance with Regulation 30(13) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, is true, correct and complete to the best of our knowledge and belief. Thanking You, Yours faithfully, For and on behalf of Bajaj Healthcare Limited Name: Monica Tanwar Designation: Company Secretary & Compliance Officer Date: October 14, 2026 Place: Thane Email ID: investors@bajajhealth.com Form A Disclosure by Bajaj Healthcare Limited regarding receipt of communication from regulatory, statutory, enforcement or judicial authority under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Regulation 30(13) – Disclosure of communication from regulatory, statutory, enforcement or judicial authority Sr. Particulars Details 1. Name of the listed company Bajaj Healthcare Limited 2. Type of communication received Order dated October 13, 2026, passed by the Hon’ble National Company Law Tribunal, Mumbai Bench, approving the acquisition of Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis. 3. Date of receipt of communication The Order was listed on October 13, 2026 and the Company downloaded it from the official website of the Hon’ble National Company Law Tribunal on October 13, 2026 4. Authority from whom Hon’ble National Company Law Tribunal, communication received Mumbai Bench 5. Brief summary of the material The Company had filed an application before the contents of the communication Hon’ble National Company Law Tribunal, received, including reasons for Mumbai Bench, seeking approval for the receipt of the communication acquisition of Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis. Vide its order dated October 13, 2026, the Hon’ble Tribunal approved the said acquisition on a going concern basis. 6. Period for which communication The order shall be effective from the date of order would be applicable, if stated i.e. October 13, 2026 until any further order(s) or directions issued by the Hon’ble National Company Law Tribunal. 7. Expected financial implications Genrx Pharmaceuticals Private Limited will be a on the listed company, if any Wholly Owned Subsidiary of Bajaj Healthcare Limited subject to the implementation of the terms specified in the NCLT order. 8. Details of any aberrations/non- Not Applicable compliances identified by the authority in the communication 9. Details of any penalty or Not Applicable restriction or sanction imposed pursuant to the communication 10. Action(s) taken by listed The Company shall take the necessary actions in company with respect to the accordance with the terms of the NCLT order. communication 11. Any other relevant information None